Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the tr···【more】
Release date：2024-08-26Recommended：284
Alpelisib, approved in 2019, has a unique efficacy against PIK3CA mutant breast ···【more】
Release date：2024-08-26Recommended：253
Alpelisib is the first PI3K inhibitor specifically for PIK3CA-mutated breast can···【more】
Release date：2024-08-26Recommended：226
Alpelisib was approved by the FDA in 2019 for the treatment of breast cancer pat···【more】
Release date：2024-08-26Recommended：263
Alpelisib is the first PI3Kα inhibitor to be used in combination with fulvestran···【more】
Release date：2024-08-26Recommended：292
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers,···【more】
Release date：2024-08-26Recommended：226
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positi···【more】
Release date：2024-08-26Recommended：258
Balversa is an innovative targeted therapy that effectively inhibits the growth ···【more】
Release date：2024-08-26Recommended：228
Balversa, a new targeted anti-cancer drug, provides new treatment hope for patie···【more】
Release date：2024-08-26Recommended：193
Balversa is a novel targeted anti-cancer drug that inhibits the FGFR signaling p···【more】
Release date：2024-08-26Recommended：145
Balversais an oral, targeted anti-cancer drug that specifically inhibits the FGF···【more】
Release date：2024-08-26Recommended：203
Balversais an oral anticancer drug targeting FGFR mutations for the treatment of···【more】
Release date：2024-08-26Recommended：259
